+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 87 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are investigating new treatment options for meningiomas that continue to grow despite local therapies like surgery or radiotherapy. This trial focuses on evaluating a precision medicine approach that combines PET-based imaging to select patients with tumors expressing somatostatin receptors and a targeted radioligand therapy called 177Lu-DOTATATE. This is the first randomized clinical trial studying this therapy in patients with meningiomas that have not responded to other treatments. Participants will be randomly assigned to one of two groups. One group receives 177Lu-DOTATATE through intravenous infusions every four weeks for a total of four cycles. The other group receives local standard care, which may include treatments like hydroxyurea, bevacizumab, sunitinib, octreotide, everolimus, or observation with supportive care, based on the investigators choice. This study is designed to compare the effects of 177Lu-DOTATATE against various standard treatments in this patient population. During the study, participants will undergo regular MRI scans to measure tumor size and progression. Researchers will also assess overall survival, neurological function, quality of life, and treatment side effects over a period extending up to two years after enrollment. Monitoring includes imaging, laboratory tests, and health questionnaires to evaluate how the disease and treatments affect participants over time.

Age: 18Years +All GendersPhase 2
19 locations
O

Actively Recruiting

Researchers are conducting an open-label, multi-site, multi-cohort phase 12 trial to evaluate ODM-212 combined with other anti-cancer therapies in adults with advanced solid tumors such as mesothelioma, pancreatic cancer, and advanced non-small cell lung cancer NSCLC. The study aims to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and effectiveness of these combinations. The trial is divided into two parts dose escalation and dose expansionoptimization. Participants receive ODM-212 tablets alongside specified anti-cancer therapies depending on their cancer type. These include ipilimumab and nivolumab for mesothelioma, gemcitabine with nab-paclitaxel for pancreatic cancer, and sotorasib for NSCLC with a KRAS G12C mutation. Each drug has specific dosing schedules, such as intravenous infusions every 3 to 6 weeks or daily oral dosing in 21-day cycles. Participants will be monitored throughout the study for dose-limiting toxicities and adverse events over an average of 2 years. They will record daily adherence to oral medications and undergo evaluations including tumor biopsies and response assessments. The study involves regular visits for treatment administration and safety monitoring, with eligibility requiring good performance status and the ability to take oral medication.

Age: 18Years +All GendersPhase 1Phase 2
23 locations
S

Actively Recruiting

Researchers are studying sacituzumab tirumotecan, alone or combined with other treatments, to understand its safety and how it affects certain advanced or unresectable gastrointestinal cancers. These include colorectal cancer, pancreatic ductal adenocarcinoma, and biliary tract cancer. The study aims to evaluate how well the cancer responds to treatment and to monitor any side effects or adverse events over time. Participants will receive sacituzumab tirumotecan either as a single agent or combined with chemotherapy, cisplatin, and pembrolizumab in different dosing schedules. Treatments are given by intravenous infusions every 2 or 3 weeks depending on the study group, continuing until the cancer worsens or treatment is not tolerated. Rescue medications and supportive care are provided to manage side effects during the treatment period. Throughout the study, participants will be closely monitored with regular visits for safety and effectiveness assessments. Researchers will track dose-limiting toxicities, adverse events, treatment discontinuations, and tumor response using established criteria. The study may last up to approximately 63 months, allowing long-term observation of survival and progression-free outcomes. Participants will also receive various laboratory tests and supportive care as needed during this period.

Age: 18Years +All GendersPhase 1Phase 2
55 locations
S

Actively Recruiting

Researchers are investigating new treatments for certain advanced solid tumors, which are cancers found mostly in organs and tissues rather than in blood or fluids. These tumors may have spread or returned after previous treatments and may not be treatable with surgery or radiation. The study focuses on evaluating MK-2010 combined with sacituzumab tirumotecan sac-TMT, an antibody-drug conjugate designed to target and destroy cancer cells. The trial aims to assess the safety and tolerability of this combination and observe how many participants experience tumor shrinkage or disappearance. Participants receive MK-2010 and sac-TMT through intravenous infusions. The trial includes two parts a safety lead-in cohort and signal-finding cohorts using the dose determined in the first part. Premedications such as histamine receptor antagonists, acetaminophen, and dexamethasone are given according to approved guidelines to manage potential side effects. Emergency medications like epinephrine are also available as needed. Throughout the study, participants undergo regular evaluations to monitor safety, side effects, and treatment responses, including adverse events and dose-limiting toxicities. Outcome measures include the objective response rate and duration of response over several years. Drug levels and immune responses are also assessed periodically. The trial spans several years, with ongoing monitoring to understand the treatments impact and tolerability.

Age: 18Years +All GendersPhase 2
4 locations
S

Actively Recruiting

Researchers are evaluating new treatment approaches for advanced ovarian cancer in people whose tumors are non-HRD positive. This study aims to find out if adding sacituzumab tirumotecan sac-TMT, a targeted therapy, as maintenance treatmentwith or without bevacizumabhelps patients live longer without their cancer worsening compared to standard care. This is a phase 3 randomized study involving participants who have completed surgery and first-line platinum-based chemotherapy. Participants receive sac-TMT intravenously on days 1, 15, and 29 of every 6-week cycle until their disease worsens or they experience prohibitive side effects. Some may also receive bevacizumab intravenously on days 1 and 22 every 6 weeks for up to 22 cycles, depending on the investigators choice. The comparison group receives either bevacizumab alone on the same schedule or is observed closely without maintenance treatment. During the study, participants will have regular evaluations to monitor their cancer status and quality of life. Researchers will measure progression-free survival for up to about 49 months and assess overall survival, adverse events, treatment discontinuation, and changes in quality of life scores for up to 78 months. Participants health will be followed long-term to understand treatment effects and safety over time.

Age: 18Years +FEMALEPhase 3
167 locations
E

Actively Recruiting

Healthy Volunteer

Hypertension is a leading risk factor for cardiovascular diseases and is often undetected because it shows no symptoms. Researchers are evaluating the performance and acceptance of the Hilo band, a cuffless blood pressure device that uses pulse wave analysis to estimate blood pressure and heart rate. This study focuses on young people aged 14 to 35, comparing the Hilo band with the traditional 24-hour Ambulatory Blood Pressure Monitoring ABPM, especially assessing both daytime and nighttime blood pressure readings. The study is a multi-center, non-interventional performance evaluation involving 40 young participants from three populations adolescents and young adults with a clinical indication for 24-hour ABPM, and healthy volunteers aged 21 to 35. Participants will use both the Hilo band and the 24-hour ABPM device over a 24-hour period, with additional assessments over three days. The Hilo band is designed to be comfortable, non-invasive, and suitable for long-term blood pressure monitoring, offering a potential alternative to the bulky and uncomfortable 24-hour ABPM cuff. Participants will be monitored for 24 hours with the 24-hour ABPM as the reference method to evaluate systolic and diastolic blood pressure measurements. Researchers will also assess the consistency of Hilo band readings over three days, its ability to classify hypertension, and participant and physician satisfaction with the device. The study includes continuous blood pressure measurements and satisfaction evaluations, aiming to provide data on the usefulness of the Hilo band in young, active populations over the course of the study.

Age: 14Years - 35YearsAll Genders
2 locations
P

Actively Recruiting

Researchers are evaluating ODM-212, a drug being studied in a first-in-human, multi-site, open-label Phase 12 clinical trial involving adults with selected advanced solid tumors that cannot be treated with curative intent. The study aims to assess the safety and side effects of ODM-212 in patients who have cancers such as mesothelioma, lung carcinoma, colorectal cancer, and others with specific genetic alterations. This research is sponsored by Orion Corporation, Orion Pharma. Participants receive ODM-212 tablets at doses of 5mg andor 40mg. The study has two parts an initial dose escalation phase to find a safe dose, followed by a dose expansion phase that includes patients with solid tumors harboring specific genetic pathway alterations. Treatments are given orally, and dosing details are adjusted based on patient response and safety observations. During the study, participants will be monitored from the first dose until one year after the last study visit to track treatment-emergent adverse events and their severity. Regular assessments include physical exams, laboratory tests, and performance status evaluations. Participants must comply with the protocol and provide informed consent. The total study duration varies based on treatment and follow-up schedules.

Age: 18Years +All GendersPhase 1Phase 2
20 locations
G

Actively Recruiting

Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.

Age: 12Years +All Genders
116 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of STL303 in adults with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. GA leads to gradual cell death in the back of the eye, causing blurry or missing central vision spots. This randomized, double-masked, multi-center study aims to find the best dose of STL303 and assess its impact on this eye condition. Participants will be randomly assigned to receive either one of two doses of oral STL303 or a placebo. The study compares these groups to understand how STL303 affects the rate of vision loss and other eye health measures. The treatment period lasts up to 104 weeks, with evaluations continuing through week 108 to monitor safety and disease progression. During the study, participants will undergo regular eye exams, including imaging scans and vision tests, to track changes in their condition. Researchers will measure the reduction in the area of eye damage, retinal sensitivity, and vision-related quality of life. Blood samples will be collected at scheduled visits to analyze how the drug is processed in the body. Participants will also record daily medication use and attend frequent study visits for assessments and safety monitoring. The total trial participation may last several years until study completion in 2029.

Age: 60Years +All GendersPhase 2
56 locations
P

Actively Recruiting

Researchers are evaluating calderasib alone and in combination with other therapies for people with advanced solid tumors that have a specific KRAS G12C mutation. The study is designed to assess the safety, how the body processes the drug pharmacokinetics, and the effectiveness of calderasib and its combinations. Participants have advanced cancers confirmed by specific tests and have often received prior treatments. Participants are assigned to one of several groups receiving different treatments. Some receive daily oral doses of calderasib alone with doses increasing up to 800 mg, adjusted as needed for safety. Others receive calderasib combined with pembrolizumab infusions every 21 days for up to 35 cycles 24 months, sometimes with additional chemotherapy drugs like carboplatin, pemetrexed, cetuximab, oxaliplatin, leucovorin, or 5-fluorouracil according to standard dosing schedules. Treatments continue until the disease progresses or participants stop. During the study, participants have regular visits for drug dosing and safety monitoring. Researchers track side effects, dose-limiting toxicities, and treatment discontinuations over months. Blood samples are taken at specific times to measure drug levels and how the body absorbs and clears calderasib. The main outcomes include safety measures up to about 56 months and response rates. This long study period helps understand how participants respond and tolerate the treatments over time.

Age: 18Years +All GendersPhase 1
75 locations

1-10 of 87

1